Vident Investment Advisory, LLC reports 58.67% increase in ownership of NVS / Novartis AG
August 14, 2018 - Vident Investment Advisory, LLC has filed a 13F-HR form disclosing ownership of 33,164 shares of Novartis AG (NYSE:NVS) with total holdings valued at $2,505,000 USD as of June 30, 2018. Vident Investment Advisory, LLC had filed a previous 13F-HR on May 14, 2018 disclosing 20,901 shares of Novartis AG at a value of $1,699,000 USD. This represents a change in shares of 58.67 percent and a change in value of 47.44 percent during the quarter.
Other investors with positions similar to Vident Investment Advisory, LLC include HPM Partners LLC, Banco Santander, S.A., Woodmont Investment Counsel Llc, MUFG Americas Holdings Corp, Frontier Wealth Management LLC, and Bokf, Na.
The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.
In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.
Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.
|NOVARTIS A G||SPONSORED ADR||66987V109||78.41||33,164||58.67||2,505||47.44||962||-156||-9.16|
|NOVARTIS A G||SPONSORED ADR||66987V109||82.62||20,901||41.40||1,699||36.91||506||-48||-3.84|
|NOVARTIS A G||SPONSORED ADR||66987V109||84.91||14,781||2.59||1,241||0.32||32||-28||-2.24|
|NOVARTIS A G||SPONSORED ADR||66987V109||84.65||14,408||3.12||1,237||6.09||37||34||2.92|
|NOVARTIS A G||SPONSORED ADR||66987V109||78.85||13,972||12.16||1,166||26.05||119||122||13.14|
|NOVARTIS A G||SPONSORED ADR||66987V109||73.53||12,457||19.03||925||21.39||146||17||2.17|
|NOVARTIS A G||SPONSORED ADR||66987V109||75.91||10,465||18.80||762||9.48||126||-60||-8.58|
|NOVARTIS A G||SPONSORED ADR||66987V109||10,465||762|
|NOVARTIS A G||SPONSORED ADR||66987V109||80.73||8,809||-0.50||696||-4.66||-4||-30||-4.17|
|NOVARTIS A G||SPONSORED ADR||66987V109||77.44||8,853||-53.06||730||-46.56||-775||139||10.17|
|NOVARTIS A G||SPONSORED ADR||66987V109||79.24||18,860||109.39||1,366||76.26||781||-190||-24.48|
|NOVARTIS A G||SPONSORED ADR||66987V109||1,366,218||18|
|NOVARTIS A G||SPONSORED ADR||66987V109||9,007||0.00||775||775||0|
|NOVARTIS A G SPONSORED||ADR||66987V109||0||-100.00||0||-100.00||0||0|
|NOVARTIS A G SPONSORED||ADR||66987V109||98.46||18,190||31.55||1,789||31.25||430||-4||-0.26|
|NOVARTIS A G||SPONSORED ADR||66987V109||13,827||1,363|
Related SEC Filings
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Arrowhead Research Corporation (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 042797209 (CUSIP Number) Scott Brown General Counsel Novartis Institutes for BioMedical Research, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Momenta Pharmaceuticals, Inc. (Name of Issuer) COMMON STOCK, Par Value $.0001 Per Share (Title of Class of Securities) 60877T100 (CUSIP Number) Dr. Christian Rehm Novartis AG Lichstrasse 35 CH 4056 Basel, Switzerland +41 61 324 1111 With a copy to: G.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R204 (CUSIP Number) Rebecca Weston Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel, Switzerland +41 61 324 7015 With a copy to: Peter Harwich Allen & Overy LLP 1221 Avenue of the Americas New York, New York 10020 +1 212 (0-1)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R204 (CUSIP Number) Rebecca Weston Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel, Switzerland +41 61 324 7015 With a copy to: Peter Harwich Allen & Overy LLP 1221 Avenue of the Americas New York, New York 10020 +1 212
Related News Stories
The biotech stocks plunge along with the broader market, as the smallcap and midcap biotech stocks retreat -17%. (41-2)
Assembly Biosciences is shaping up to be a major player in the future of Hepatitis B therapeutics. (14-0)
Thank you very much and good morning, and good afternoon, everybody. Before we start, I just wanted to read to you the safe harbor statements. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. (1-1)
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (3-0)
Endocyte Inc. (NASDAQ: ECYT) shares were up sharply on Thursday after it was announced that Novartis A.G. (NYSE: NVS) would acquire the company. The transaction was unanimously approved by the board of directors of Endocyte, but it is still subject to Endocyte stockholder and regulatory approvals. (1-1)
as of ET